iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
iTeos Therapeutics (Nasdaq: ITOS) has appointed David Feltquate, M.D., Ph.D., as Chief Medical Officer. Dr. Feltquate will oversee the company's clinical development and regulatory strategies. He brings nearly 20 years of experience in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement.
Prior to joining iTeos, Dr. Feltquate served as Chief Medical Officer at Palleon Pharmaceuticals and held leadership positions at Novartis and Bristol Myers Squibb. Notably, he was responsible for the clinical development of the first PD-1 inhibitor at Bristol Myers Squibb. Dr. Feltquate's appointment comes at a pivotal moment for iTeos as it aims to become a leading oncology company and advance its pipeline, including its TIGIT franchise.
iTeos Therapeutics (Nasdaq: ITOS) ha nominato David Feltquate, M.D., Ph.D. come Capo Ufficio Medico. Il Dott. Feltquate supervisionerà lo sviluppo clinico e le strategie regolatorie dell'azienda. Porta con sé quasi 20 anni di esperienza nello sviluppo clinico dell'immuno-oncologia, nella medicina traslazionale e nell'avanzamento dei test diagnostici.
Prima di unirsi a iTeos, il Dott. Feltquate ha ricoperto il ruolo di Capo Ufficio Medico presso Palleon Pharmaceuticals e ha occupato posizioni di leadership in Novartis e Bristol Myers Squibb. È importante sottolineare che è stato responsabile dello sviluppo clinico del primo inibitore PD-1 presso Bristol Myers Squibb. La nomina del Dott. Feltquate avviene in un momento cruciale per iTeos, mentre punta a diventare una delle principali aziende oncologiche e a far avanzare il proprio portafoglio, inclusa la sua linea di prodotti TIGIT.
iTeos Therapeutics (Nasdaq: ITOS) ha nombrado a David Feltquate, M.D., Ph.D. como Director Médico. El Dr. Feltquate supervisará el desarrollo clínico y las estrategias regulatorias de la empresa. Aporta casi 20 años de experiencia en el desarrollo clínico de inmuno-oncología, medicina traslacional y el avance de ensayos diagnósticos.
Antes de unirse a iTeos, el Dr. Feltquate fue Director Médico en Palleon Pharmaceuticals y ocupó puestos de liderazgo en Novartis y Bristol Myers Squibb. Cabe destacar que fue responsable del desarrollo clínico del primer inhibidor de PD-1 en Bristol Myers Squibb. La designación del Dr. Feltquate llega en un momento clave para iTeos, ya que busca convertirse en una empresa líder en oncología y avanzar en su cartera, incluida su franquicia TIGIT.
iTeos Therapeutics (Nasdaq: ITOS)는 David Feltquate, M.D., Ph.D.를 최고 의학 책임자(CMO)로 임명했습니다. Feltquate 박사는 회사의 임상 개발 및 규제 전략을 감독할 것입니다. 그는 면역종양학 임상 개발, 전환 의학 및 진단 분석법 발전에 있어 거의 20년의 경험을 가지고 있습니다.
iTeos에 합류하기 전, Feltquate 박사는 Palleon Pharmaceuticals에서 최고 의학 책임자로 재직했으며, Novartis와 Bristol Myers Squibb에서 리더십 직책을 맡았습니다. 특히, 그는 Bristol Myers Squibb에서 첫 번째 PD-1 억제제의 임상 개발을 담당했습니다. Feltquate 박사의 임명은 iTeos가 주요 온코로지 기업으로 성장하고 TIGIT 프랜차이즈를 포함한 파이프라인을 발전시키려는 중요한 시점에서 이루어졌습니다.
iTeos Therapeutics (Nasdaq: ITOS) a nommé David Feltquate, M.D., Ph.D. au poste de Directeur Médical. Dr. Feltquate supervisera le développement clinique et les stratégies réglementaires de l'entreprise. Il apporte près de 20 ans d'expérience dans le développement clinique de l'immuno-oncologie, la médecine translationnelle et l'avancement des tests diagnostiques.
Avant de rejoindre iTeos, Dr. Feltquate a été Directeur Médical chez Palleon Pharmaceuticals et a occupé des postes de direction chez Novartis et Bristol Myers Squibb. Notamment, il a été responsable du développement clinique du premier inhibiteur de PD-1 chez Bristol Myers Squibb. La nomination de Dr. Feltquate intervient à un moment décisif pour iTeos alors que l'entreprise vise à devenir un leader en oncologie et à faire progresser son pipeline, y compris sa gamme TIGIT.
iTeos Therapeutics (Nasdaq: ITOS) hat David Feltquate, M.D., Ph.D. zum Chief Medical Officer ernannt. Dr. Feltquate wird die klinische Entwicklung und die regulatorischen Strategien des Unternehmens leiten. Er bringt fast 20 Jahre Erfahrung in der klinischen Entwicklung von Immunonkologie, translationaler Medizin und dem Fortschritt diagnostischer Verfahren mit.
Vor seinem Eintritt bei iTeos war Dr. Feltquate Chief Medical Officer bei Palleon Pharmaceuticals und hatte Führungspositionen bei Novartis und Bristol Myers Squibb inne. Besonders hervorzuheben ist, dass er für die klinische Entwicklung des ersten PD-1-Inhibitors bei Bristol Myers Squibb verantwortlich war. Die Ernennung von Dr. Feltquate erfolgt zu einem entscheidenden Zeitpunkt für iTeos, da das Unternehmen anstrebt, ein führendes Onkologieunternehmen zu werden und sein Portfolio, einschließlich der TIGIT-Produktfamilie, voranzubringen.
- Appointment of experienced Chief Medical Officer with 20 years in immuno-oncology
- Dr. Feltquate's expertise in clinical development and regulatory strategies
- Strengthening of leadership team at a important time for company growth
- Dr. Feltquate's track record in developing successful oncology drugs (e.g., first PD-1 inhibitor)
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company’s clinical development and regulatory strategies.
“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “His leadership experience, track record in immuno-oncology drug development, and insights into biomarker development will prove invaluable as we continue to advance our pipeline. We look forward to the integral role he will play in shaping our clinical development strategy and in strengthening our organization as we continue in a defining year for the company.”
Dr. Feltquate brings to iTeos nearly 20 years of immuno-oncology clinical development, translational medicine, and diagnostic assay advancement experience. Prior to joining iTeos, he was Chief Medical Officer at Palleon Pharmaceuticals where he oversaw the clinical strategy and development of its glyco-immunology therapeutics pipeline. Before that, Dr. Feltquate was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Previously, he held numerous leadership positions at Bristol Myers Squibb including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab / Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, Dr. Feltquate was responsible for the clinical development of the first PD-1 inhibitor from proof of concept through initial registrations in non-small cell lung cancer, melanoma, and renal cell carcinoma. Dr. Feltquate earned a B.S. in Biology from the Massachusetts Institute of Technology and an M.D./Ph.D. in Immunology from the University of Massachusetts Medical School. He completed internal medicine training at Dartmouth Hitchcock Medical Center and medical oncology training at Memorial Sloan Kettering Cancer Center.
“I am delighted to join iTeos at a time when the company is accelerating its TIGIT franchise and strategically focused on building a rich pipeline of new targets for patients in need,” said Dr. Feltquate. “Being part of a company that is at the forefront of developing an innovative oncology pipeline, ingrained in a scientifically disciplined, data driven approach, represents an incredible opportunity to bring novel and potentially transformative therapies to patients.”
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
About Belrestotug (EOS-448/ GSK4428859A)
Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an important inhibitory receptor which contributes to the suppression of innate and adaptive immune responses against cancer. As an optimized high-affinity, potent anti-TIGIT mAb, belrestotug is designed to enhance the antitumor response through a multifaceted immune modulatory mechanism by engaging with TIGIT and FcγR, a key regulator of immune responses which induces cytokine release and antibody dependent cellular cytotoxicity (ADCC). The therapeutic candidate is progressing in multiple indications in collaboration with GSK.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of David Feltquate’s appointment as the Company’s Chief Medical Officer and the potential to bring novel and transformative therapies to patients.
These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, negative developments in the field of immuno-oncology, and regulatory, court or agency decisions; and those risks identified under the heading “Risk Factors” in iTeos’ Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
Who is the new Chief Medical Officer of iTeos Therapeutics (ITOS)?
What is Dr. Feltquate's background before joining iTeos Therapeutics (ITOS)?
What will be Dr. Feltquate's responsibilities at iTeos Therapeutics (ITOS)?
How might Dr. Feltquate's appointment impact iTeos Therapeutics (ITOS)?
